<DOC>
	<DOC>NCT01009424</DOC>
	<brief_summary>This study will assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of RO5024118 following repeated inhalation in patients with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD). Patients will be randomized to receive multiple inhaled doses of R7103, as compared with placebo. The target sample size is approximately 30 individuals.</brief_summary>
	<brief_title>A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Male and female patients 4070 years of age, inclusive. Body Mass Index 1832 kg/m2, inclusive. Female patients must be surgically sterile or post menopausal for the past year confirmed by a negative hormone panel. Male patients and their partners of childbearing potential must use two methods of contraception, one of which must be a barrier method for the duration of the study and for 7 days after last dose. Diagnosis of moderatetosevere COPD (GOLD Stage IIIII). Current smoker or history of smoking in the last three months. Use of continuous daily long term oxygen therapy or requirement for oxygen therapy during exercise. History of cardiac conduction abnormalities or ventricular tachyarrhythmias. Exacerbation of COPD within 8 weeks before first dosing.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>